Notably, exosomes engineered to display immune checkpoint modulators (PD-1, OX40L) along with tumor-targeting antibodies (anti-CD3, anti-EGFR) have demonstrated potent T-cell activation and the robust suppression of EGFR-positive tumors in murine models [58]. The gene discussed is EGFR; the disease is neoplasm.